Prostate Cancer Screening and Risk-Stratified Treatment: Updated Guidance for Clinicians
核心洞察
Prostate cancer (搜索) is the second most common cancer in US men, with more than 290,000 new diagnoses expected annually and about 34,000 deaths each year.
Screening relies on the prostate-specific antigen (PSA) (搜索) test, with shared decision-making recommended given varying guidelines and potential benefits and harms.
Newly diagnosed patients should be risk-stratified by T stage, Gleason score/grade group, PSA level, and tumor volume to guide treatment selection.
Prostate cancer (搜索) remains the second most common cancer in US men and the second leading cause of cancer death in this population, underscoring the importance of evidence-based screening and risk-stratified treatment. More than 290,000 men are expected to be diagnosed each year, and approximately 34,000 deaths occur annually — a figure that has increased over the past decade as the population ages.
Guidelines for screening vary across major medical organizations, underscoring the need to engage patients in shared decision-making and counsel them about the potential benefits and harms of testing. When screening is undertaken, it is based on the prostate-specific antigen (PSA) (搜索) test, with digital rectal examination used selectively as an adjunct.
Screening Recommendations and Risk Factors
Robert Reiter, MD, chief of the Division of Urologic Oncology at the David Geffen School of Medicine at UCLA, emphasized that prostate cancer (搜索) is typically asymptomatic in its early stages. "For the most part, prostate cancer doesn't cause any symptoms. It's really silent until it becomes extremely advanced," he said, noting that advanced disease can cause bone pain, difficulty urinating, weight loss, and loss of appetite. "It makes screening really the only way to detect it early, when it's potentially curable."
The No. 1 risk factor is family history and genetics. A man with a first-degree male relative — a father or brother — with prostate cancer (搜索) has twice the incidence of the disease compared to the general population. Genetic risk can also arise from BRCA1 (搜索) or BRCA2 (搜索) mutations, which are associated not only with increased incidence but also with more aggressive prostate cancers. Genetics likely accounts for at least 70% of prostate cancer cases, making it potentially the most heritable of cancers. African American men have the highest incidence of prostate cancer among different ethnic populations.
For screening timing, Dr. Reiter recommends that men without a family history and who are not African American begin PSA testing at age 50. For those with a family history or who are African American, testing should begin at age 40. A PSA level at age 40 is a strong predictor of future risk: if it is less than 1 or 1.5 ng/mL, testing can likely be deferred until age 45 or 50, whereas higher levels warrant yearly testing. The benefits of screening appear greatest for men younger than 70.
Diagnostic Pathway
PSA testing is the first step in diagnosis. If the PSA is elevated or increasing, clinicians generally obtain an MRI of the prostate or additional urine and blood tests to assess the likelihood of cancer. If the MRI shows an abnormality, the patient undergoes a biopsy to confirm the diagnosis and determine the cancer grade.
Men with an abnormal PSA level should have a repeat test within a few months before proceeding to biomarker testing, referral to urology, biopsy, and potentially imaging. The pathologist grades the biopsy on a scale of 1 to 5; grades 1 and some grade 2 cancers are slow-growing and may not require immediate treatment, while grades 3 to 5 represent more aggressive disease.
Risk Stratification and Treatment Selection
Patients with newly diagnosed prostate cancer (搜索) should be risk-stratified using clinical tumor (T) stage as determined by digital rectal examination, International Society of Urological Pathology grade group (Gleason score), PSA level, and tumor volume on biopsy. Treatment options vary by risk category.
Active surveillance is recommended for patients with low-risk disease, typically those with grade group 1/Gleason score of 6 (3 + 3). For patients with favorable intermediate-risk prostate cancer (搜索), treatment options include active surveillance, radiation therapy, or radical prostatectomy. For patients with unfavorable intermediate- or high-risk prostate cancer and an estimated life expectancy greater than 10 years, options are radical prostatectomy or radiation therapy plus androgen deprivation therapy.
For patients with PSA levels greater than 40 ng/dL, a Gleason score of 9 or higher, or locally advanced prostate cancer (搜索), treatment with radiation therapy and androgen deprivation therapy can additionally include concurrent abiraterone plus prednisone for 2 years. Focal ablation is also an option for some patients.
Dr. Reiter noted that roughly 30% to 50% of diagnosed patients do not need treatment, or at least do not need immediate treatment, and can be monitored. For localized or early-stage disease, options range from surgery to remove the entire prostate, robotic surgery, various forms of radiation therapy, focal (partial gland) therapy, and medical therapies.
Prognosis and Treatment Considerations
Prognosis varies by disease features. Men with low-risk prostate cancer (搜索) are much more likely to die from other causes, whereas those with distant metastases have a 5-year relative survival rate of 38.3%. Dr. Reiter noted that prostate cancer "is generally not a lethal cancer for most men" and "can be highly curable through screening if it's caught early before it has metastasized."
Common treatment side effects include impotence, sexual dysfunction, urinary incontinence, changes in bowel habits, and fatigue. Robotic surgery adds precision and has reduced many side effects, though it does not eliminate them entirely.
Ongoing research at UCLA Health (搜索) spans the breadth of the field, including clinical trials in diagnosis, PET imaging for more accurate early-stage detection, radiation oncology, and experimental approaches such as immunotherapy or vaccines for prostate cancer (搜索).